Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global, Randomized, Adaptive Trial to Evaluate the Combination of Tazemetostat with Revlimid plus Rituxan (R2) for Follicular Lymphoma Patients in the Second-Line or Later Treatment Setting

Trial Profile

A Global, Randomized, Adaptive Trial to Evaluate the Combination of Tazemetostat with Revlimid plus Rituxan (R2) for Follicular Lymphoma Patients in the Second-Line or Later Treatment Setting

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Tazemetostat (Primary)
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Epizyme
  • Most Recent Events

    • 30 Oct 2019 According to an Epizyme media release, Epizyme gained alignment with FDA on this single confirmatory trial to support a submission for full approval.Site initiation is underway and the safety run-in portion of the trial is on track to begin in the fourth quarter of 2019.
    • 26 Feb 2019 According to an Epizyme media release, the company plans to initiate this study in mid-2019.
    • 20 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top